Bacteria

Viruses

Cancer

Our Therapeutic Candidates

Trellis has derived five human monoclonal antibody (mAbs) therapeutics against bacterial, viral and cancer indications. All candidates are in preclinical development and will reach Phase I clinical trials by 2019.

Biofilm Tile HCMV Tile Pan-influenza Tile RSV Tile Cancer Tile

In vivo and in vitro experimental data show our antibodies possess superior binding affinity, broad-spectrum capabilities, and efficacy compared to alternative therapies

© 2010-2018 TRELLIS BIOSCIENCE. ALL RIGHTS RESERVED.